Has Sundaram Ravikumar, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,788,935 in general payments to Sundaram Ravikumar, MD across 71 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sundaram Ravikumar, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sundaram Ravikumar, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sundaram Ravikumar, MD

Vascular Surgery · Dobbs Ferry, NYNPI 1750441069

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $1,753,426 of the $1,788,935 with a category attached, or 98.0%. Teleflex Medical Incorporated accounts for 98.0% of it on its own, with 17 other manufacturers making up the rest. Among vascular surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,788,935in general payments, 2019–2025

Across 71 payments — averaging $25,196 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Teleflex Medical Incorporated$1.8M
Angiodynamics, Inc.$34K
Abbott$363
Silk Road Medical, Inc.$304
AstraZeneca$250
Catheter Precision, Inc. FKA Ra Medical Systems, Inc.$224
plus $767 from 12 others

What the payments were for

Royalty or licence$1,753,42698%
Food & beverage$1,9080%
Education$14,4001%
Other$19,2001%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Teleflex Medical Incorporated	28	$1,753,426
Angiodynamics, Inc.	7	$33,600
Abbott	7	$363
Silk Road Medical, Inc.	2	$304
AstraZeneca	2	$250
Catheter Precision, Inc. FKA Ra Medical Systems, Inc.	5	$224
Endologix LLC	2	$176
Smith+Nephew	2	$141
W. L. Gore & Associates, Inc.	1	$125
Lilly USA, LLC	4	$67
Cardiva Medical, Inc.	2	$57
Tactile Systems Technology Inc	2	$45
Resmed Corp	1	$35
Bard Peripheral Vascular, Inc.	2	$30
Heartflow, Inc.	1	$30
Amgen	1	$27
Boston Scientific	1	$18
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Percutaneous Solutions: PERCUVANCE & MiniLap brands$557,911
Percutaneous: Percuvance System$554,051
Percutaneous: MiniLap System with MiniGrip Handle$259,168
PERCUVANCE$214,772
DEKNATEL$167,524
VenaCure 1470 Pro$24,000
EVLT$9,600
ENROUTE Transcarotid Neuroprotection System$304
ENHANCE Transcarotid Peripheral Access Kit$304
FARXIGA$250
ENROUTE .014 Guidewire$199
ENROUTE Transcarotid Stent$199
JETi Peripheral Catheter$149
Torus Stent Graft System$146
ENDOCROSS Device$146
GORE EXCLUDER AAA Endoprosthesis$125
Santyl$124
DABRA$116
Perclose ProStyle$116
ENROUTE Transcarotid Stent System$105

How this compares

$1,788,935 in reported general payments places this provider in the 95th percentile of 405 vascular surgery providers in New York.

See all vascular surgery providers in New York →

Medicare billing

Part B allowed, 2024

$451,156

Medicare patients

111

Services billed

534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	11	$7,269
ClopidogrelClopidogrel Bisulfate	16	$15

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Dobbs Ferry

Gary GelbfishNew York$1.9M
Antonios GasparisHuntington$1.5M
Sonya NoorBuffalo$991K
John LantisNew York$922K
Brian DerubertisNew York$714K
James McKinseyNew York$616K
Peter FariesNew York$494K
Robert RheeBrooklyn$338K
Ajit RaoNew York$294K
Jeffrey HnathAlbany$289K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →